VALIDAMYCIN H, A NEW PSEUDO-TETRASACCHARIDE ANTIBIOTIC

Sir:

Validamycin A has been used to control some diseases caused by *Rhizoctonia solani*, particularly sheath blight of rice plants. Validamycin A is the major component of the validamycin complex produced by *Streptomyces hygroscopicus* subsp. *limoneus*. The validamycin complex comprises the ten components, validamycins $A \sim G$ and validoxylamines A, B and G (Fig. 1)^{1~3)}. In the course of purification of pseudo-tetrasaccharides, validamycins C, E and F, we found a new pseudo-tetrasaccharide, validamycin H.

In this communication, we report the isolation, structure elucidation and biological activity against *R. solani* of the new pseudo-tetrasaccharide, validamycin H.

The crude validamycin complex (120 g), prepared from the fermentation broth as previously reported^{1,4)}, was passed through a column of

Table 1. ¹³C NMR chemical shifts of validamycin H.

Table 1. C I	TITLE CHEIMICAL SIMILS	or variating on 11.
Carbon	Validamycin A	Validamycin H
C-1	56.53 d	56.60 d
C-2	75.96 d	75.96 d
C-3	75.54 d	75.80 d
C-4	87.10 d	87.75 d
C-5	40.23 d	40.20 d
C-6	29.67 t	29.64 t
C-7	64.60 t	64.71 t
C-1'	55.20 d	55.22 t
C-2'	125.97 d	126.05 d
C-3'	141.98 s	142.05 s
C-4'	74.28 d	74.34 d
C-5'	76.49 d	76.54 d
C-6'	72.23 d	72.29 d
C-7'	64.37 t	64.41 t
C-1"	105.67 d	105.87 d
C-2"	76.22 d	76.17 d
C-3"	78.43 d	78.37 d
C-4"	72.23 d	72.33 d
C-5"	78.80 d	77.58 d
C-6"	63.34 t	71.61 t
C-1""		105.51 d
C-2""		75.96 d
C-3"		78.45 d
C-4""		72.44 d
C-5'''		78.84 d
C-6'''		63.58 t

^a δ (ppm) from 3-(trimethylsilyl)propionate (TSP) in D₂O.

Amberlite IR-120B (H $^+$) and the column was eluted with 0.5 N ammonium hydroxide. The eluate was concentrated and applied onto a column of Amberlite CG-50 (NH $_4$ $^+$). The effluent and washings were concentrated and lyophilized to give the validamycin complex (59 g). Approximately 10 g portions of the validamycin complex were chromatographed on a column (4.2 × 90 cm) of Bio-Gel P-2 (200 ~ 400 mesh) and tetrasaccharides fraction was pooled. This fraction was further purified on a column of Dowex 1-X2 (OH $^-$, 100 ml) and eluted with H $_2$ O to give validamycins C (61 mg), H (60 mg)

Table 2. ¹H NMR data of validamycins A and H (δ in ppm^a, J in Hz).

Proton	Validamycin A	Validamycin H
1-H	3.287 (br q)	3.290 (br q)
2-H	3.633 (dd, J=9.5, 4.0)	3.639 (dd, J=10.1,
		4.0)
3-H	3.748 (t, J=9.5)	3.757 (dd, J=10.1,
		9.3)
4-H	3.515 (dd, J=10.0,	3.515 (dd, J=10.5,
	9.5)	9.3)
5-H	2.097 (m)	2.103 (m)
$6-H_{ax}$	1.366 (ddd, $J = 14.5$,	1.364 (ddd, $J = 14.8$,
	13.0, 2.8)	13.2, 2.8)
$6-H_{eq}$	1.960 (dt, $J = 14.5$,	1.967 (dt, $J = 14.8$,
7.11	3.2)	3.2)
7-H _{a,b}	3.788 (d, J=4.3)	3.786 (d, $J=4.6$)
1'-H	3.382 (br t, $J=4.9$)	3.367 (br s)
2'-H	6.046 (dq, $J=4.9$, 1.5)	6.048 (dq, $J = 5.0$, 1.5)
4'-H 5'-H	4.095 (br d, $J=5.7$)	4.097 (br d, $J=5.9$) 3.636 (dd, $J=9.5$, 5.9)
6'-H	3.633 (dd, J =9.0, 5.7) 3.635 (dd, J =9.0, 4.0)	3.636 (dd, $J=9.5$, 3.9)
7'-H _a	4.138 (br d, $J = 13.9$)	4.139 (br d, $J = 13.8$)
7'-H _a	4.251 (dq, $J = 13.9$)	4.253 (dq, $J = 13.8$,
, -11b	1.0)	1.0)
1″-H	4.528 (d, J=8.0)	4.532 (d, J=8.0)
2"-H	3.347 (dd, J=9.1, 8.0)	3.367 (dd, J=9.3, 8.0)
3″-H	3.524 (t, J=9.1)	3.513 (t, $J=9.3$)
4"-H	3.435 (dd, J=9.5, 9.1)	3.497 (dd, J=9.8, 9.3)
5"-H	3.497 (m)	3.675 (m)
6"-H _a	3.744 (dd, J = 12.3,	3.874 (dd, J=12.4,
-	5.8)	6.3)
6"-H _b	3.916 (dd, J=12.3,	4.224 (dd, J = 12.4,
,	2.1)	2.1)
1'''-H		4.512 (d, J=8.0)
2'''-H		3.332 (dd, J=9.3, 8.0)
3'''-H		3.513 (t, J=9.3)
4′′′-H		3.402 (dd, J=9.8, 9.3)
5′′′-H		3.463 (m)
6'''-H _a		3.675 (dd, J=12.4,
		5.6)
6′′′-H _b		3.922 (dd, J=12.4,
		2.1)

a See footnote in Table 1.

Fig. 1. Structure of the validamycin complex.

Validoxylamine A	$R_1 = H$	$R_2 = H$	$R_3 = H$	$R_4 = H$	$R_5 = H$	$R_6 = H$
Validoxylamine B	$R_1 = H$	$R_2 = H$	$R_3 = OH$	$R_4 = H$	$R_5 = H$	$R_6 = H$
Validoxylamine G	$R_1 = OH$	$R_2 = H$	$R_3 = H$	$R_4 = H$	$R_5 = H$	$R_6 = H$
Validamycin A	$R_1 = H$	$R_2 = H$	$R_3 = H$	$R_4 = \beta$ -D-Glc	$R_5 = H$	$R_6 = H$
Validamycin B	$R_1 = H$	$R_2 = H$	$R_3 = OH$	$R_4 = \beta$ -D-Glc	$R_5 = H$	$R_6 = H$
Validamycin C	$R_1 = H$	$R_2 = H$	$R_3 = H$	$R_4 = \beta$ -D-Glc	$R_5 = \alpha$ -D-Glc	$R_6 = H$
Validamycin D	$R_1 = H$	$R_2 = \alpha$ -D-Glc	$R_3 = H$	$R_4 = H$	$R_5 = H$	$R_6 = H$
Validamycin E	$R_1 = H$	$R_2 = H$	$R_3 = H$	$R_4 = \alpha - D - Glc(1-4) -$	$R_5 = H$	$R_6 = H$
				β -D-Glc		
Validamycin F	$R_1 = H$	$R_2 = H$	$R_3 = H$	$R_4 = \beta$ -D-Glc	$R_5 = H$	$R_6 = \alpha$ -D-Glc
Validamycin G	$R_1 = OH$	$R_2 = H$	$R_3 = H$	$R_4 = \beta$ -D-Glc	$R_5 = H$	$R_6 = H$
Validamycin H	$R_1 = H$	$R_2 = H$	$R_3 = H$	$R_4 = \beta$ -D-Glc(1-6)-	$R_5 = H$	$R_6 = H$
				β-D-Glc		

Glc: Glucopyranosyl.

and a mixture (238 mg) of validamycins E and F in order of elution from the column. The Rf values of validamycins C, E, F and H on TLC (Silica gel 60F₂₅₄, Merck) were all 0.14 with PrOH-AcOH-H₂O (4:1:1) as the developing system, and 0.14, 0.21, 0.21 with BuOH-MeOH-CHCl₃-concd NH₄OH (4:5:2:5).

Validamycin H: Colorless amorphous; $[\alpha]_D^{25} + 74.9^\circ$ (c 1, H₂O). Acid hydrolysis of validamycin H using Dowex 50W-X8 (H⁺) gave D-glucose and validoxylamine A as an aglycone.

The structure of validamycin H was determined by ¹³C NMR, ¹H NMR, DEPT, ¹³C-¹H COSY, ¹H-¹H COSY and NOESY experiments with a Jeol JNM-GX400 spectrometer in comparison with the data of validamycin A. The 13C and 1H NMR spectral data of validamycins A and H are listed in Tables 1 and 2, respectively. The coupling constants of the anomeric protons 1"-H (J=8.0 Hz) and 1"'-H (J=8 Hz) in ¹H NMR spectrum of validamycin H demonstrated the modes of glucosidic linkages as both β . As shown in Tables 1 and 2, validamycins A and H exhibited the identical chemical shifts to each other for the chemical shifts of validoxylamine A moiety. In addition, the further glucoside formation for a pseudo-trisaccharide (β-D-glucopyranosylvalidoxylamine A) produced a 8.27-ppm

Table 3. Effect of the validamycin complex on *Rhizoctonia solani* in "dendroid-test method".

Compound	Dendroid-test method (µg/ml) ^a	
Validoxylamine A	1.00	
Validoxylamine B	50	
Validoxylamine G	2.50	
Validamycin A	0.01	
Validamycin B	0.50	
Validamycin C	10	
Validamycin D	25	
Validamycin E	0.01	
Validamycin F	0.01	
Validamycin G	0.50	
Validamycin H	0.05	

Minimum concentration causing abnormal branching.

downfield shift for C-6" in 13 C NMR, 0.130 and 0.308 ppm downfield shifts for 6"-H in 1 H NMR. By NMR studies mentioned above and the NOE between 1"-H and 4-H, and 1"'-H and 6"-H_b observed by NOESY, the positions of glucosidic linkages were determined at C-4 and C-6", respectively. Therefore the structure of validamycin H was shown to be 6"-O- β -D-glucopyranosylvalidamycin A (Fig. 1).

Validamycin H exhibited 5-fold weaker activity against *R. solani* by the "dendroid-test method"⁵ than validamycins E and F, which are α-D-glucopyranosylvalidamycin A (Table 3). The glucoside introduction into the hydroxymethyl group of validoxylamine A (validamycins C and D) causes the reduction of activity against *R. solani*. The reduction of activity in validamycin H may be due to the suppression of permeability of the antibiotic into the pathogen⁶) by the glucoside introduction into the hydroxymethyl group (C-6") of the glucosyl residue.

Acknowledgments

We express our thanks to Dr. HARUHISA KIZU (School of Pharmacy, Hokuriku University) for measurement of NMR spectra.

NAOKI ASANO YUKIHIKO KAMEDA KATSUHIKO MATSUI

School of Pharmacy, Hokuriku University, Kanazawa 920-11, Japan

> Satoshi Horii Hiroshi Fukase

Central Research Division, Takeda Chemical Industries Ltd., Osaka 532, Japan

(Received March 3, 1990)

References

- IWASA, T.; E. HIGASHIDE, H. YAMAMOTO & M. SHIBATA: Studies on validamycins, new antibiotics.
 II. Production biological properties of validamycins A and B. J. Antibiotics 24: 107~113, 1971
- HORII, S.; Y. KAMEDA & K. KAWAHARA: Studies on validamycins, new antibiotics. VIII. Isolation and characterization of validamycins C, D, E and F. J. Antibiotics 25: 48~53, 1972
- KAMEDA, Y.; N. ASANO, T. YAMAGUCHI, K. MATSUI,
 S. HORII & H. FUKASE: Validamycin G and validoxylamine G, new members of the validamycins.
 J. Antibiotics 39: 1491 ~ 1494, 1986
- IWASA, T.; Y. KAMEDA, M. ASAI, S. HORII & K. MIZUNO: Studies on validamycins, new antibiotics. IV. Isolation and characterization of validamycins A and B. J. Antibiotics 24: 119~123, 1971
- IWASA, T.; E. HIGASHIDE & M. SHIBATA: Studies on validamycins, new antibiotics. III. Bioassay methods for the determination of validamycin. J. Antibiotics 24: 114~118, 1971
- ASANO, N.; T. YAMAGUCHI, Y. KAMEDA & K. MATSUI: Effect of validamycins on glycohydrolases of Rhizoctonia solani. J. Antibiotics 40: 526~532, 1987